Open AccessEvaluation of a newly developed chemiluminescence immunoassay for detecting cardiac troponin T
Author(s) -
Wang Jingkun,
Fang Yizhen,
Li Peihua,
Lin Huayue,
Jin Hongwei,
Gao Lei,
Ge Shengxiang,
Zhang ZhongYing
Publication year - 2018
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.22311
Subject(s) - chemiluminescence , detection limit , electrochemiluminescence , chromatography , troponin complex , immunoassay , chemistry , linear range , roche diagnostics , medicine , troponin , immunology , myocardial infarction , antibody
Background To evaluate the performance of a chemiluminescence detection kit for cardiac troponin T ( cTnT ). Methods According to the “Guiding principles on performance analysis of diagnostic reagents in vitro” and the Clinical and Laboratory Standards Institute ( CLSI ) Guidelines, we assessed the detection limit, linear range, reportable range, accuracy, precision, cross reactivity, interference factors, and matrix effect of the kit, and compared these parameters with that of the commercial electrochemiluminescence detection kit for cTnT (Roche). Results The minimum detection limit of the kit was 0.01 ng/ mL . The linear range was 0.01 ng/ mL ‐25 ng/ mL . The reportable range was from 0.01 ng/ mL to 100 ng/ mL . Precision within the batch was 2.9%‐6.4%, and precision between batches was 6.0%; the accuracy was good and the recovery rate reached 96.2%. The cross‐reaction test demonstrated that there was no reactivity between cTnT and a variety of troponins. Test results deviated by less than ±10% in the presence of hemoglobin ≤1000 μg/ mL , bilirubin ≤250 μg/ mL , triglycerides ≤11.25 mg/ mL , and rheumatoid factor ≤206 U/ mL , suggesting that kit results were not significantly interfered with these factors. Results from the matrix‐effect assessment revealed absence of a matrix effect in the tested serum samples. Correlation study revealed that the performance of the kit was very consistent with that of the Roche electrochemiluminescence detection kit (Kappa = 0.900, P < .001) with a high correlation ( r = .903, P < .001) and a total matching rate of 95.00%. Conclusion The performance of the evaluated chemiluminescence immunoquantitation kit for cTnT detection was acceptable in all tested parameters, fulfilling requirements for clinical applications.